Clinical trials: Mucopolysaccharidosis IH/S

Mucopolysaccharidosis I, Hurler's Syndrome

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

• Completed
• Age: All ages
• Phase 3
• Results posted

This study is being conducted to collect additional long-term efficacy and safety data of Aldurazyme® (laronidase) patients with MPS I disease.

Conditions

Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome

Trial name

NCT00146770

Testing

Aldurazyme

Where

25 sites in United States, Brazil and 5 more

Volunteers

45 people

Sponsor

Genzyme, a Sanofi Company